Summary | |
---|---|
Symbol | CD226 |
Name | CD226 molecule |
Aliases | DNAM-1; DNAM1; PTA1; TLiSA1; CD226 antigen; DNAX accessory molecule 1; DNAX accessory molecule-1; T lineage- ...... |
Chromosomal Location | 18q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane Single-pass type I membrane protein |
Domain |
PF07686 Immunoglobulin V-set domain |
Function |
Involved in intercellular adhesion, lymphocyte signaling, cytotoxicity and lymphokine secretion mediated by cytotoxic T-lymphocyte (CTL) and NK cell (PubMed:8673704). Cell surface receptor for NECTIN2. Upon ligand binding, stimulates T-cell proliferation and cytokine production, including that of IL2, IL5, IL10, IL13, and IFNG. Competes with PVRIG for NECTIN2-binding (PubMed:26755705). |
Biological Process |
GO:0001819 positive regulation of cytokine production GO:0001906 cell killing GO:0001909 leukocyte mediated cytotoxicity GO:0001910 regulation of leukocyte mediated cytotoxicity GO:0001912 positive regulation of leukocyte mediated cytotoxicity GO:0002228 natural killer cell mediated immunity GO:0002250 adaptive immune response GO:0002274 myeloid leukocyte activation GO:0002347 response to tumor cell GO:0002367 cytokine production involved in immune response GO:0002370 natural killer cell cytokine production GO:0002418 immune response to tumor cell GO:0002420 natural killer cell mediated cytotoxicity directed against tumor cell target GO:0002423 natural killer cell mediated immune response to tumor cell GO:0002429 immune response-activating cell surface receptor signaling pathway GO:0002431 Fc receptor mediated stimulatory signaling pathway GO:0002440 production of molecular mediator of immune response GO:0002443 leukocyte mediated immunity GO:0002449 lymphocyte mediated immunity GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002694 regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0002697 regulation of immune effector process GO:0002699 positive regulation of immune effector process GO:0002700 regulation of production of molecular mediator of immune response GO:0002702 positive regulation of production of molecular mediator of immune response GO:0002703 regulation of leukocyte mediated immunity GO:0002705 positive regulation of leukocyte mediated immunity GO:0002706 regulation of lymphocyte mediated immunity GO:0002708 positive regulation of lymphocyte mediated immunity GO:0002712 regulation of B cell mediated immunity GO:0002714 positive regulation of B cell mediated immunity GO:0002715 regulation of natural killer cell mediated immunity GO:0002717 positive regulation of natural killer cell mediated immunity GO:0002718 regulation of cytokine production involved in immune response GO:0002720 positive regulation of cytokine production involved in immune response GO:0002727 regulation of natural killer cell cytokine production GO:0002729 positive regulation of natural killer cell cytokine production GO:0002757 immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0002768 immune response-regulating cell surface receptor signaling pathway GO:0002819 regulation of adaptive immune response GO:0002821 positive regulation of adaptive immune response GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002831 regulation of response to biotic stimulus GO:0002833 positive regulation of response to biotic stimulus GO:0002834 regulation of response to tumor cell GO:0002836 positive regulation of response to tumor cell GO:0002837 regulation of immune response to tumor cell GO:0002839 positive regulation of immune response to tumor cell GO:0002855 regulation of natural killer cell mediated immune response to tumor cell GO:0002857 positive regulation of natural killer cell mediated immune response to tumor cell GO:0002858 regulation of natural killer cell mediated cytotoxicity directed against tumor cell target GO:0002860 positive regulation of natural killer cell mediated cytotoxicity directed against tumor cell target GO:0002889 regulation of immunoglobulin mediated immune response GO:0002891 positive regulation of immunoglobulin mediated immune response GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules GO:0007157 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0008037 cell recognition GO:0016064 immunoglobulin mediated immune response GO:0019724 B cell mediated immunity GO:0031341 regulation of cell killing GO:0031343 positive regulation of cell killing GO:0031349 positive regulation of defense response GO:0032609 interferon-gamma production GO:0032649 regulation of interferon-gamma production GO:0032729 positive regulation of interferon-gamma production GO:0033003 regulation of mast cell activation GO:0033005 positive regulation of mast cell activation GO:0042267 natural killer cell mediated cytotoxicity GO:0042269 regulation of natural killer cell mediated cytotoxicity GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response GO:0045576 mast cell activation GO:0045954 positive regulation of natural killer cell mediated cytotoxicity GO:0050865 regulation of cell activation GO:0050867 positive regulation of cell activation GO:0060368 regulation of Fc receptor mediated stimulatory signaling pathway GO:0060369 positive regulation of Fc receptor mediated stimulatory signaling pathway GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules |
Molecular Function |
GO:0005178 integrin binding GO:0050839 cell adhesion molecule binding |
Cellular Component |
GO:0005913 cell-cell adherens junction GO:0009897 external side of plasma membrane GO:0045121 membrane raft GO:0098552 side of membrane GO:0098589 membrane region GO:0098857 membrane microdomain |
KEGG |
hsa04514 Cell adhesion molecules (CAMs) |
Reactome |
R-HSA-1280218: Adaptive Immune System R-HSA-168256: Immune System R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell |
Summary | |
---|---|
Symbol | CD226 |
Name | CD226 molecule |
Aliases | DNAM-1; DNAM1; PTA1; TLiSA1; CD226 antigen; DNAX accessory molecule 1; DNAX accessory molecule-1; T lineage- ...... |
Chromosomal Location | 18q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between CD226 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between CD226 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | CD226 |
Name | CD226 molecule |
Aliases | DNAM-1; DNAM1; PTA1; TLiSA1; CD226 antigen; DNAX accessory molecule 1; DNAX accessory molecule-1; T lineage- ...... |
Chromosomal Location | 18q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of CD226 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | CD226 |
Name | CD226 molecule |
Aliases | DNAM-1; DNAM1; PTA1; TLiSA1; CD226 antigen; DNAX accessory molecule 1; DNAX accessory molecule-1; T lineage- ...... |
Chromosomal Location | 18q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of CD226 in various data sets.
|
Points in the above scatter plot represent the mutation difference of CD226 in various data sets.
|
Summary | |
---|---|
Symbol | CD226 |
Name | CD226 molecule |
Aliases | DNAM-1; DNAM1; PTA1; TLiSA1; CD226 antigen; DNAX accessory molecule 1; DNAX accessory molecule-1; T lineage- ...... |
Chromosomal Location | 18q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD226. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | CD226 |
Name | CD226 molecule |
Aliases | DNAM-1; DNAM1; PTA1; TLiSA1; CD226 antigen; DNAX accessory molecule 1; DNAX accessory molecule-1; T lineage- ...... |
Chromosomal Location | 18q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD226. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD226. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | CD226 |
Name | CD226 molecule |
Aliases | DNAM-1; DNAM1; PTA1; TLiSA1; CD226 antigen; DNAX accessory molecule 1; DNAX accessory molecule-1; T lineage- ...... |
Chromosomal Location | 18q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD226. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | CD226 |
Name | CD226 molecule |
Aliases | DNAM-1; DNAM1; PTA1; TLiSA1; CD226 antigen; DNAX accessory molecule 1; DNAX accessory molecule-1; T lineage- ...... |
Chromosomal Location | 18q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of CD226 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | CD226 |
Name | CD226 molecule |
Aliases | DNAM-1; DNAM1; PTA1; TLiSA1; CD226 antigen; DNAX accessory molecule 1; DNAX accessory molecule-1; T lineage- ...... |
Chromosomal Location | 18q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between CD226 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | CD226 |
Name | CD226 molecule |
Aliases | DNAM-1; DNAM1; PTA1; TLiSA1; CD226 antigen; DNAX accessory molecule 1; DNAX accessory molecule-1; T lineage- ...... |
Chromosomal Location | 18q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting CD226 collected from DrugBank database. |
There is no record. |